Doca: Medgend

Search instead for coca

Doca FDA Approved Drugs

AKTEN [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

3.5% (ophthalmic gel)

Akorn^{Oct 7, 2008}

Method of inducing topical anesthesia in the eye.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ASCLERA [Polidocanol^{C₁₂H₂₆O(C₂H₄O)n}]

10mg/2ml (5mg/ml) (intravenous solution)

20mg/2ml (10mg/ml) (intravenous solution)

Chemisch Fbrk Krsslr^{Mar 30, 2010}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CUBICIN [Daptomycin^{C₇₂H₁₀₁N₁₇O₂₆}]

500mg/vial (intravenous powder)

Cubist Pharms Llc^{Sep 12, 2003}

Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CUBICIN RF [Daptomycin^{C₇₂H₁₀₁N₁₇O₂₆}]

500mg/vial (intravenous powder)

Cubist Pharms Llc^{Jul 6, 2016}

Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

EMLA [Lidocaine^{C₁₄H₂₂N₂O} : Prilocaine^{C₁₃H₂₀N₂O}]

2.5% : 2.5% (topical cream)

Actavis Labs Ut Inc^{Dec 30, 1992}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

GLYDO [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

2% (topical jelly)

Sagent Pharms^{Apr 28, 2014}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LARYNG-O-JET KIT [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

4% (topical solution)

Intl Medication^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE [Lidocaine^{C₁₄H₂₂N₂O}]

5% (topical patch)

Actavis Labs Ut Inc^{Aug 23, 2012}
Alkem Labs Ltd^{Mar 10, 2017}
Amneal Pharms^{Aug 7, 2015}
Fougera Pharms Inc^{Approved Prior To Jan 1, 1982}
Glenmark Pharms Ltd^{Sep 9, 2016}
Mylan Technologies^{Aug 7, 2015}
Septodont Inc^{May 23, 2011}
Taro^{Approved Prior To Jan 1, 1982}
Teligent Pharma Inc^{Feb 1, 2016}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE AND PRILOCAINE [Lidocaine^{C₁₄H₂₂N₂O} : Prilocaine^{C₁₃H₂₀N₂O}]

2.5% : 2.5% (topical cream)

Fougera Pharms^{Aug 18, 2003}
Hi Tech Pharma^{Sep 25, 2003}
Tolmar^{Aug 27, 2003}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE HYDROCHLORIDE [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

0.5% (injection injectable)

1% (injection injectable)

2% (topical jelly)

20% (injection injectable)

4% (topical solution)

Hospira^{May 17, 1984}
Mylan Labs Ltd^{Dec 8, 2010}
Intl Medication^{Approved Prior To Jan 1, 1982}
Luitpold^{Approved Prior To Jan 1, 1982}
Luitpold Pharms Inc^{Aug 14, 2015}
Akorn^{Feb 12, 2003}
Hi Tech Pharma^{Jul 10, 1995}
Watson Labs Inc^{Mar 23, 2011}
Wockhardt^{Nov 18, 1982}
Teligent Pharma Inc^{Mar 12, 2014}
Vintage^{Feb 27, 2007}
West-ward Pharms Int^{Apr 3, 1985}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

200mg/100ml (injection injectable)

B Braun^{Apr 8, 1992}
Baxter Hlthcare^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

400mg/100ml (injection injectable)

B Braun^{Apr 8, 1992}
Baxter Hlthcare^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

800mg/100ml (injection injectable)

B Braun^{Apr 8, 1992}
Baxter Hlthcare^{Feb 22, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

5% (spinal injectable)

Hospira^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE [Epinephrine^{C₉H₁₃NO₃} : Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

0.005mg/ml : 0.5% (injection injectable)

0.005mg/ml : 1.5% (injection injectable)

0.005mg/ml : 2% (injection injectable)

0.01mg/ml : 1% (injection injectable)

0.01mg/ml : 2% (injection injectable)

0.02mg/ml : 2% (injection injectable)

Hospira^{Jun 21, 1988}
Eastman Kodak^{Feb 26, 1993}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

0.5% (injection injectable)

1% (injection injectable)

2% (injection injectable)

Hospira^{Jul 31, 1984}
Fresenius Kabi Usa^{Jul 24, 1985}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

1% (injection injectable)

1.5% (injection injectable)

2% (injection injectable)

20% (injection injectable)

4% (injection injectable)

Aurobindo Pharma Ltd^{Mar 14, 2013}
Fresenius Kabi Usa^{Approved Prior To Jan 1, 1982}
Hospira^{Approved Prior To Jan 1, 1982}
Mylan Labs Ltd^{Sep 27, 2010}
Intl Medication^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

1% (injection injectable)

2% (injection injectable)

Hospira^{Sep 28, 1998}

LIDOCAINE HYDROCHLORIDE VISCOUS [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

2% (oral solution)

Vintage^{Feb 27, 2007}

LIDOCAINE VISCOUS [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

2% (oral solution)

West-ward Pharms Int^{Apr 26, 1985}

LIDODERM [Lidocaine^{C₁₄H₂₂N₂O}]

5% (topical patch)

Teikoku Pharma Usa^{Mar 19, 1999}

LIGNOSPAN FORTE [Epinephrine Bitartrate^{C₉H₁₃NO₃C₄H₆O₆} : Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

eq 0.02mg base/ml : 2% (injection injectable)

Deproco^{Jan 22, 1985}

LIGNOSPAN STANDARD [Epinephrine Bitartrate^{C₉H₁₃NO₃C₄H₆O₆} : Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

eq 0.01mg base/ml : 2% (injection injectable)

Deproco^{Jan 22, 1985}

LTA II KIT [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

4% (topical solution)

Hospira^{Approved Prior To Jan 1, 1982}

OCTOCAINE [Epinephrine^{C₉H₁₃NO₃} : Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

0.01mg/ml : 2% (injection injectable)

0.02mg/ml : 2% (injection injectable)

Septodont^{Approved Prior To Jan 1, 1982}

ORAQIX [Lidocaine^{C₁₄H₂₂N₂O} : Prilocaine^{C₁₃H₂₀N₂O}]

2.5% : 2.5% (periodontal gel)

Dentsply Pharm^{Dec 19, 2003}

Management of pain and discomfort associated with peridontal scaling and root planning procedures by application of an eutectic mixture of local anesthetics to peridontal pockets.

PLIAGLIS [Lidocaine^{C₁₄H₂₂N₂O} : Tetracaine^{C₁₅H₂₄N₂O₂}]

7% : 7% (topical cream)

Taro Pharms^{Jun 29, 2006}

SYNERA [Lidocaine^{C₁₄H₂₂N₂O} : Tetracaine^{C₁₅H₂₄N₂O₂}]

70mg : 70mg (topical patch)

Galen Specialty^{Jun 23, 2005}

VARITHENA [Polidocanol^{C₁₂H₂₆O(C₂H₄O)n}]

180mg/18ml (10mg/ml) (intravenous solution)

Provensis^{Nov 25, 2013}

A method of generating an injectable foam of controlled density and bubble size.
A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities.
A method of using a sclerosing agent for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous (gsv) system above and below the knee.

XYLOCAINE [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

0.5% (injection injectable)

1% (injection injectable)

1.5% (injection injectable)

2% (injection injectable)

Fresenius Kabi Usa^{Approved Prior To Jan 1, 1982}
Oak Pharms^{Approved Prior To Jan 1, 1982}

XYLOCAINE 4% PRESERVATIVE FREE [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

4% (injection injectable)

Fresenius Kabi Usa^{Approved Prior To Jan 1, 1982}

XYLOCAINE PRESERVATIVE FREE [Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

1% (injection injectable)

2% (injection injectable)

20% (injection injectable)

4% (injection injectable)

Fresenius Kabi Usa^{Jan 19, 1988}

XYLOCAINE W/ EPINEPHRINE [Epinephrine^{C₉H₁₃NO₃} : Lidocaine Hydrochloride^{C₁₄H₂₂N₂OClHH₂O}]

0.005mg/ml : 0.5% (injection injectable)

Fresenius Kabi Usa^{Approved Prior To Jan 1, 1982}

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Felter's Materia Medica on Doca

ADONIS VERNALIS
The whole plant of Adonis vernalis, Linné. (Nat. Ord. Ranunculaceae). Southern Europe, Siberia, and Labrador. Dose, 1/2 to 3 grains. Common Name:... / ...greatly affected. Scudder valued adonis in heart-strain from overexertion; Hale recommended it in endocarditis and in weak and irregular heart action resulting from chronic nephritis. Wilcox used it i... / ...in epilepsy, administering it with bromide of potassium. It should not be given when there is gastro-intestinal irritation or inflammation. ¹

CONVALLARIA^CONVA
The rhizome and rootlets of Convallaria majalis, Linné (Nat. Ord. Liliaceae.) Common Name: Lily of the Valley. Principal Constituents.Two... / ..., preferable to digitalis, and it is often valuable in the early stages of rheumatic carditis and endocarditis, using it in fractional doses. Convallaria is of less service in stenosis of the aorta th...¹

CRATAEGUS^CRAN6
The ripe fruit and bark of (1) Crataegus Oxyacantha, Linné, and (2) other species of Crataegus. (Nat. Ord. Rosaceae) 1. England and other parts... / ... organ. Among the conditions in which crataegus is accredited with good work are angina pectoris, endocarditis, myocarditis, and pericarditis, valvular incompetency with or without enlargement of the ... / ...trial; and as yet with no rational explanation of its reputed powers. The smaller doses are suggested as more likely to succeed than full doses.¹

LYCOPUS^LYSH2
The whole herb Lycopus virginicus, Linné (Nat. Ord. Labiatae). Common in shady, moist and boggy places throughout the United States. Dose, 1 to... / ...oyed on account of its offensive action upon the stomach. Administered to patients suffering from endocarditis and pericarditis it has sometimes subdued the inflammation. It is a good remedy in cardia... / ...in simple diarrhea (lientery), dysenteric diarrhea, and especially in the diarrhea of phthisis, and the gastric disturbances of the drunkard.¹

SPIGELIA
The dried rhizome and roots of Spigelia marilandica, Linné (Nat. Ord. Loganiaceae). Southern United States; less plentiful in northern parts of... / ...tracted to spigelia, chiefly of homeopathic origin, as a remedy in heart affections, particularly endocarditis of rheumatic origin and to guard against relapses of cardiac rheumatism. Cardiac neuralgi... / ...Mix. Sig.: One teaspoonful every two hours. Large doses are said to debilitate the heart.¹

Physician's Therapeutics Memoranda on Doca

ENDOCARDITIS
In the early stage, control heart’s action with aconite or veratrum viride; calomel and opium or morphine; leeches or ice bag over pre cordium. Later sustain heart’s action with digitalis. If of rheuma tic or syphilitic origin adopt appropriate general treatment. In cases of acute articular rheumatism, watch for indications of cardiac inflammation and meet symptoms promptly.²

References

1) Felter, Harvey Wickes, 1922, The Eclectic Materia Medica, Pharmacology and Therapeutics, Cincinnati, Ohio.
2) Nelson, Baker & Co., 1904, Physician's Handy Book of Materia Medica and Therapeustics, Detroit, Michigan.

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Doca FDA Approved Drugs

Felter's Materia Medica on Doca

Physician's Therapeutics Memoranda on Doca

References